유전성 혈관부종 치료제 시장 규모, 점유율, 동향 분석 보고서 : 치료법별, 용도별, 지역별, 부문별 예측(2026-2033년)

Hereditary Angioedema Therapeutics Market Summary

The global hereditary angioedema therapeutics market size was estimated at USD 3.60 billion in 2025 and is projected to reach USD 8.18 billion by 2033, growing at a CAGR of 10.43% from 2026 to 2033. The global hereditary angioedema therapeutics market is expanding due to increasing diagnosis rates and greater clinical awareness of rare genetic disorders.

Improved access to specialized testing has enabled earlier identification of patients, which supports timely treatment initiation. The availability of targeted therapies that address underlying disease pathways has strengthened treatment outcomes and patient confidence. Pharmaceutical innovation has introduced convenient administration options, including subcutaneous and oral formulations, which improve adherence. Rising prevalence reporting across developed and emerging regions continues to create sustained demand for effective therapies.

Advancements in biologics and novel drug classes represent another major growth driver for the market. Long-acting prophylactic therapies have reduced attack frequency and improved quality of life for patients, which has increased adoption among physicians. Oral kallikrein inhibitors and gene-targeted approaches under development are expanding the future treatment landscape. Strong clinical trial activity and regulatory approvals have accelerated commercialization timelines for innovative therapies. For instance, December 2025, HCPLive reported that the U.S. Food and Drug Administration had approved three new hereditary angioedema treatments in 2025 over three months, including garadacimab gxii, Andembry, in June, sebetralstat, Ekterly, in July, and donidalorsen, Dawnzera, in August, in a disease affecting about 1 in 50,000 people globally and nearly 6,000 in the United States. Prior to these approvals, 9 therapies were available, increasing to 12 by 2026, reflecting the expansion of oral and injectable options. Strategic collaborations between biotechnology firms and larger pharmaceutical companies have further enhanced research capabilities and global distribution reach.

Healthcare infrastructure improvements and the expansion of specialty care networks are further contributing to market growth. Increased involvement of immunologists and rare disease specialists has strengthened disease management standards and treatment utilization. Patient advocacy initiatives and education programs have encouraged treatment uptake and long-term therapy compliance. Favorable reimbursement coverage in several regions has improved patient access to high-cost biologic treatments. For instance, in December 2025, Rare Disease Advisor reported that the U.S. Food and Drug Administration had approved berotralstat, marketed as ORLADEYO, as the first oral plasma kallikrein inhibitor prophylactic therapy for hereditary angioedema in children aged 2 to 11 years, extending prior approval for patients 12 years and older. The pediatric approval was based on the APeX P trial involving 29 patients aged 2 to 11 years, 48.3 percent female, with a mean age of 8 years and a mean onset at 2 years, demonstrating sustained reductions in monthly attack rates and a peak median concentration of 3.9 hours, range 0.9 to 6.0 hours. Growing investment in rare disease research continues to support innovation and competitive market expansion.

Global Hereditary Angioedema Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global hereditary angioedema therapeutics market based on treatment, end use, route of administration, and region:

• Treatment Outlook (Revenue, USD Million, 2021 - 2033)
• C1-Inhibitor Concentrates
• Bradykinin B2 Receptor Antagonist
• Kallikrein Inhibitor
• Others
• End use Outlook (Revenue, USD Million, 2021 - 2033)
• Prophylaxis
• On-demand
• Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
• Intravenous
• Subcutaneous
• Oral
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Treatment
  • 1.2.2. End Use
  • 1.2.3. Route of Administration
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Hereditary Angioedema Therapeutics Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Hereditary Angioedema Therapeutics Market: Treatment Business Analysis

• 4.1. Treatment Market Share, 2025 & 2033
• 4.2. Treatment Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2021 to 2033 (USD Million)
• 4.4. C1-Inhibitor Concentrates
  • 4.4.1. C1-Inhibitor Concentrates Market, 2021 - 2033 (USD Million)
• 4.5. Bradykinin B2 Receptor Antagonist
  • 4.5.1. Bradykinin B2 Receptor Antagonist Market, 2021 - 2033 (USD Million)
• 4.6. Kallikrein Inhibitor
  • 4.6.1. Kallikrein Inhibitor Market, 2021 - 2033 (USD Million)
• 4.7. Others
  • 4.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Hereditary Angioedema Therapeutics Market: End Use Business Analysis

• 5.1. End Use Market Share, 2025 & 2033
• 5.2. End Use Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 5.4. Prophylaxis
  • 5.4.1. Prophylaxis Market, 2021 - 2033 (USD Million)
• 5.5. On-demand
  • 5.5.1. On-demand Market, 2021 - 2033 (USD Million)

Chapter 6. Hereditary Angioedema Therapeutics Market: Route of Administration Business Analysis

• 6.1. Route of Administration Market Share, 2025 & 2033
• 6.2. Route of Administration Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Route of administration, 2021 to 2033 (USD Million)
• 6.4. Intravenous
  • 6.4.1. Intravenous Market, 2021 - 2033 (USD Million)
• 6.5. Subcutaneous
  • 6.5.1. Subcutaneous Market, 2021 - 2033 (USD Million)
• 6.6. Oral
  • 6.6.1. Oral Market, 2021 - 2033 (USD Million)

Chapter 7. Hereditary Angioedema Therapeutics Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2025 & 2033
• 7.2. Regional Market Dashboard
• 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 7.4. North America
  • 7.4.1. North America Hereditary Angioedema Therapeutics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. End Use Disease Prevalence
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. Reimbursement Framework
    • 7.4.2.5. U.S. Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. End Use Disease Prevalence
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Reimbursement Framework
    • 7.4.3.5. U.S. Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. End Use Disease Prevalence
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Reimbursement Framework
    • 7.4.4.5. Mexico Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. End Use Disease Prevalence
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement Framework
    • 7.5.2.5. Uk Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. End Use Disease Prevalence
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement Framework
    • 7.5.3.5. Germany Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. End Use Disease Prevalence
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. Reimbursement Framework
    • 7.5.4.5. France Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. End Use Disease Prevalence
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Reimbursement Framework
    • 7.5.5.5. Italy Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. End Use Disease Prevalence
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Reimbursement Framework
    • 7.5.6.5. Spain Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.7. Denmark
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. End Use Disease Prevalence
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Reimbursement Framework
    • 7.5.7.5. Denmark Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. End Use Disease Prevalence
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Reimbursement Framework
    • 7.5.8.5. Sweden Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. End Use Disease Prevalence
    • 7.5.9.3. Regulatory Framework
    • 7.5.9.4. Reimbursement Framework
    • 7.5.9.5. Norway Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. End Use Disease Prevalence
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement Framework
    • 7.6.2.5. Japan Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. End Use Disease Prevalence
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement Framework
    • 7.6.3.5. China Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. End Use Disease Prevalence
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement Framework
    • 7.6.4.5. India Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. End Use Disease Prevalence
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement Framework
    • 7.6.5.5. Australia Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. End Use Disease Prevalence
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Reimbursement Framework
    • 7.6.6.5. South Korea Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. End Use Disease Prevalence
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Reimbursement Framework
    • 7.6.7.5. Thailand Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. End Use Disease Prevalence
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Reimbursement Framework
    • 7.7.2.5. Japan Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. End Use Disease Prevalence
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Reimbursement Framework
    • 7.7.3.5. China Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.8. Middle East and Africa
  • 7.8.1. Middle East and Africa Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. End Use Disease Prevalence
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Reimbursement Framework
    • 7.8.2.5. South Africa Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. End Use Disease Prevalence
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Reimbursement Framework
    • 7.8.3.5. Saudi Arabia Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. End Use Disease Prevalence
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. Reimbursement Framework
    • 7.8.4.5. UAE Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. End Use Disease Prevalence
    • 7.8.5.3. Regulatory Framework
    • 7.8.5.4. Reimbursement Framework
    • 7.8.5.5. Kuwait Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis
• 8.3. Company Categorization
• 8.4. Strategy Mapping
• 8.5. Company Profiles/Listing
  • 8.5.1. BioCryst Pharmaceuticals, Inc.
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Treatment Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. Ionis Pharmaceuticals
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Treatment Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. CSL
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Treatment Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Attune Pharmaceuticals
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Treatment Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Adverum Biotechnologies, Inc.
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Treatment Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. KalVista Pharmaceuticals, Inc.
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Treatment Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Takeda Pharmaceutical Company Limited
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Treatment Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. Pharming
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Treatment Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. Sanofi
    • 8.5.9.1. Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Treatment Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. Pharvaris B.V.
    • 8.5.10.1. Overview
    • 8.5.10.2. Financial Performance
    • 8.5.10.3. Treatment Benchmarking
    • 8.5.10.4. Strategic Initiatives
  • 8.5.11. Arrowhead Pharmaceuticals, Inc.
    • 8.5.11.1. Overview
    • 8.5.11.2. Financial Performance
    • 8.5.11.3. Treatment Benchmarking
    • 8.5.11.4. Strategic Initiatives